Codexis plans $103m IPO this week

- Last updated on GMT

Related tags: Initial public offering

Biocatalysis specialist Codexis aims to raise $103m in another initial public offering (IPO) on the Nasdaq Global Market.

The firm, which makes enzymes used in the production of pharmaceuticals and biofuels, has filed several​ IPOs during its seven year existence that were subsequently withdrawn.

Now however, according to documents filed with the US Securities and Exchange Commission last Friday, the California, US-based company has made some 6m shares available to investors for between $13 and $15 each.

Despite deriving a significant amount of its business from oil companies like Shell and Chevron, Codexis also counts firms like Pfizer, Merck and Teva among its drug industry customers.

More recently​ the firm partnered with active pharmaceutical ingredient (API) maker Ampac Fine Chemicals and Indian contract research and manufacturing services (CRAMS) group Dishman.

Related news

Show more

Related products

show more

Accelerate your supply chain as pressures intensify

Accelerate your supply chain as pressures intensify

William Reed | 17-Sep-2018 | Technical / White Paper

Food, Drink and Non-Food manufacturers are under pressure. Range reviews, massive retail mergers, the backlash against plastic packaging and the ongoing...

SQ-USP-Brochure-Thumb-AP-CC

NEW…sugarcane derived USP Squalane from Aprinnova

APRINNOVA – A joint venture of AMYRIS and NIKKOL Group | 26-Feb-2018 | Product Brochure

To date, topical formulation chemists have been restricted to using Squalane derived from the harvesting of shark livers. Neossance Squalane USP, derived...

Related suppliers

Follow us

Products

View more

Webinars